Savara Inc

24 sie 2026, 22:01 UTC

Savara Inc. will present Phase 3 trial results for molgramostim at the European Respiratory Society Congress in 2026. Shares are higher in after-market trading.

21 sie 2026, 19:36 UTC

Savara Inc. granted inducement awards to eight new employees, including options for 74,500 shares. Shares are higher since Thursday's close.

20 sie 2026, 20:02 UTC

Savara Inc shares are lower amid a broader market downturn, influenced by disappointing sales growth from major retailers like Walmart Inc. Trading volume remains unusually high.

19 sie 2026, 19:26 UTC

Savara Inc is trading higher today, maintaining upward momentum since Tuesday's close. The stock moved from a session low to a pre-market high.

18 sie 2026, 23:01 UTC

Savara Inc shares declined in after-market trading, falling below their 20-day moving average after an earlier surge. No specific news was identified to explain the volatility.

17 sie 2026, 19:46 UTC

Savara Inc is trading lower today, retracing from earlier gains and near the lower end of its one-month range. No specific news was identified.

14 sie 2026, 19:44 UTC

Savara Inc shares are higher today amid increased trading volume. No specific company news was identified to explain the price movement.

13 sie 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Wednesday. The stock saw high trading volume amid no specific news.

12 sie 2026, 19:56 UTC

Savara Inc. shares are higher following Citizens' reaffirmation of its Outperform rating and $10 price target ahead of the MOLBREEVI PDUFA date.

11 sie 2026, 19:11 UTC

Savara Inc shares are lower today amid unusually high market volume. No specific news was identified to explain the decline.

10 sie 2026, 23:01 UTC

Savara Inc shares are lower in after-market trading, showing notable volatility without any specific news to explain the decline.

7 sie 2026, 19:36 UTC

Savara Inc is trading higher, benefiting from broader market gains following a weaker-than-expected jobs report that may delay Federal Reserve interest rate hikes.

6 sie 2026, 20:06 UTC

Savara Inc shares are higher today, recovering from earlier declines and trading above their 20-day moving average. No specific news was identified for the move.

5 sie 2026, 19:36 UTC

Savara Inc. shares are higher as the company advances its Biologics License Application for molgramostim, with a key PDUFA date approaching.

4 sie 2026, 23:01 UTC

Savara Inc shares are trading higher in after-market hours, showing significant volatility with no specific news identified to explain the price movement.

3 sie 2026, 20:06 UTC

Savara Inc is declining today, diverging from recent higher closes. Broader market indices, including the S&P 500 and Nasdaq 100, are gaining.

31 lip 2026, 20:06 UTC

Savara Inc shares are lower despite the European Patent Office granting a patent for MOLBREEVI, effective through March 2041. The stock remains near its one-month low.

30 lip 2026, 20:09 UTC

Savara Inc shares rise after the European Patent Office grants a patent for MOLBREEVI, providing protection until March 2041.

29 lip 2026, 19:47 UTC

Savara Inc's shares are lower, marking five consecutive sessions of decline. Broader market performance is mixed as traders await the Federal Reserve's interest rate decision.

28 lip 2026, 19:16 UTC

Savara Inc. shares are lower today amid ongoing price weakness. Broader markets like the FTSE 100 and DAX are showing resilience despite this decline.

27 lip 2026, 14:02 UTC

Savara Inc shares are higher during Monday's session, reaching their peak at 9:30 AM ET. No specific news was identified to explain the movement.

24 lip 2026, 20:02 UTC

Savara Inc shares are lower today, continuing a decline since Thursday amid high market volume. Broader market sentiment is affected by recent oil price volatility.

21 lip 2026, 17:41 UTC

Savara Inc. shares are advancing today amid strong trading volume. The broader market is also positive, led by gains in technology stocks.

20 lip 2026, 20:06 UTC

Savara Inc shares are higher, continuing their advance from Friday's close. Broader market sentiment remains mixed amid ongoing geopolitical concerns.